{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma+of+Head%2FNeck&page=43", "query": { "condition": "Carcinoma of Head/Neck", "page": 43 }, "page_size": 10 }, "pagination": { "page": 43, "page_size": 10, "total_count": 1995, "total_pages": 200, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma+of+Head%2FNeck&page=44&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma+of+Head%2FNeck&page=42&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-23T10:58:39.180Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03878979", "title": "Preoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent/Metastatic SCCHN", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma", "Head and Neck Cancer", "Head and Neck Cancer Metastatic" ], "interventions": [ { "name": "Nivolumab 480mg and surgical resection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2019-07-08", "completion_date": "2023-10-17", "has_results": true, "last_update_posted_date": "2024-11-21", "last_synced_at": "2026-10-23T10:58:39.180Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03878979" }, { "nct_id": "NCT00126568", "title": "Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anaplastic Thyroid Cancer", "Recurrent Thyroid Cancer" ], "interventions": [ { "name": "sorafenib tosylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2005-06", "completion_date": "2011-09", "has_results": true, "last_update_posted_date": "2018-01-19", "last_synced_at": "2026-10-23T10:58:39.180Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00126568" }, { "nct_id": "NCT02258659", "title": "Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Human Papilloma Virus Infection", "Stage III Squamous Cell Carcinoma of the Oropharynx", "Stage IVA Squamous Cell Carcinoma of the Oropharynx", "Stage IVB Squamous Cell Carcinoma of the Oropharynx" ], "interventions": [ { "name": "paclitaxel albumin-stabilized nanoparticle formulation", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "hydroxyurea", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "OTHER", "PROCEDURE" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2014-09-22", "completion_date": "2024-09-06", "has_results": true, "last_update_posted_date": "2024-09-24", "last_synced_at": "2026-10-23T10:58:39.180Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02258659" }, { "nct_id": "NCT02551159", "title": "Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Squamous Cell Carcinoma of the Head and Neck" ], "interventions": [ { "name": "MEDI4736", "type": "BIOLOGICAL" }, { "name": "Tremelimumab", "type": "BIOLOGICAL" }, { "name": "MEDI4736+Tremelimumab", "type": "BIOLOGICAL" }, { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "5-fluorouracil (5FU)", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 823, "start_date": "2015-10-15", "completion_date": "2021-05-21", "has_results": true, "last_update_posted_date": "2021-10-13", "last_synced_at": "2026-10-23T10:58:39.180Z", "location_count": 19, "location_summary": "Aurora, Colorado • Washington D.C., District of Columbia • Fort Myers, Florida + 14 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02551159" }, { "nct_id": "NCT00258323", "title": "Radiotherapy,Chemotherapy,Before and After Surgery in Advanced Esophageal or Gastroesophageal Junction Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer" ], "interventions": [ { "name": "cisplatin", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "Iressa", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2005-10", "completion_date": "2010-02", "has_results": false, "last_update_posted_date": "2015-09-30", "last_synced_at": "2026-10-23T10:58:39.180Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00258323" }, { "nct_id": "NCT02454179", "title": "Study of the Combination of Acalabrutinib (ACP-196) and Pembrolizumab in Advanced Head and Neck Squamous Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma of the Head and Neck" ], "interventions": [ { "name": "pembrolizumab", "type": "DRUG" }, { "name": "Acalabrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Acerta Pharma BV", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2015-05", "completion_date": "2018-07", "has_results": true, "last_update_posted_date": "2019-09-12", "last_synced_at": "2026-10-23T10:58:39.180Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT02454179" }, { "nct_id": "NCT06805617", "title": "A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Salivary Gland Cancer", "Advanced Salivary Gland Carcinoma", "Metastatic Salivary Gland Cancer", "Adenoid Cystic Carcinoma" ], "interventions": [ { "name": "Ivonescimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2025-02-26", "completion_date": "2027-07-01", "has_results": false, "last_update_posted_date": "2026-10-21", "last_synced_at": "2026-10-23T10:58:39.180Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06805617" }, { "nct_id": "NCT01534897", "title": "Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Papillary Thyroid Carcinoma" ], "interventions": [ { "name": "GSK2118436", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2012-07", "completion_date": "2014-03", "has_results": true, "last_update_posted_date": "2017-03-15", "last_synced_at": "2026-10-23T10:58:39.180Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01534897" }, { "nct_id": "NCT01137162", "title": "Clinical and Pathologic Studies of Patients Undergoing Treatment With EGFR Inhibitors", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Anal, Colon, and Rectal Cancers", "Head and Neck Cancer", "Lung Cancer", "Colon Cancer", "Colonic Neoplasms", "Colorectal Neoplasms", "Colon/Rectal Cancer", "Colon/Rectal Cancer Colon Cancer", "Colon/Rectal Cancer Rectal Cancer", "Colon/Rectal Cancer Anal Cancer", "Head and Neck Cancers", "Head and Neck Cancers Lip", "Head and Neck Cancers Oral Cavity", "Head and Neck Cancers Nasopharynx", "Head and Neck Cancers Oropharynx", "Head and Neck Cancers Hypopharynx", "Head and Neck Cancers Larynx", "Head and Neck Cancers Trachea", "Lung Cancer Non-Small Cell Cancer (NSCLC)", "Lung Cancer Small Cell Lung Cancer (SCLC)" ], "interventions": [], "intervention_types": [], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2008-08", "completion_date": "2011-10", "has_results": false, "last_update_posted_date": "2016-07-22", "last_synced_at": "2026-10-23T10:58:39.180Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01137162" }, { "nct_id": "NCT03715946", "title": "Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Squamous Cell of Head and Neck", "Oropharynx Squamous Cell Carcinoma" ], "interventions": [ { "name": "Nivolumab Injection", "type": "DRUG" }, { "name": "Radiotherapy (RT)", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Robert L. Ferris, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2018-11-16", "completion_date": "2024-03-31", "has_results": true, "last_update_posted_date": "2025-01-13", "last_synced_at": "2026-10-23T10:58:39.180Z", "location_count": 3, "location_summary": "Atlanta, Georgia • Portland, Oregon • Pittsburgh, Pennsylvania", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Portland", "state": "Oregon" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03715946" } ] }